These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 11706392)

  • 1. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
    Schneider JW; Chang AY; Garratt A
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):22-8. PubMed ID: 12138394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
    Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
    Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
    Perez EA
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer therapy-associated cardiotoxicity and signaling in the myocardium.
    Zuppinger C; Suter TM
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):141-6. PubMed ID: 20386457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
    Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
    Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
    Leemasawat K; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    Cell Mol Life Sci; 2020 Apr; 77(8):1571-1589. PubMed ID: 31650186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
    Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
    Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
    de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
    Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herceptin and the heart--a molecular modifier of cardiac failure.
    Chien KR
    N Engl J Med; 2006 Feb; 354(8):789-90. PubMed ID: 16495390
    [No Abstract]   [Full Text] [Related]  

  • 13. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
    Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
    Seemann I; te Poele JA; Song JY; Hoving S; Russell NS; Stewart FA
    Breast Cancer Res Treat; 2013 Oct; 141(3):385-95. PubMed ID: 24091769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.
    Chien KR
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):9-14; discussion 92-100. PubMed ID: 11236034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.
    Horie T; Ono K; Nishi H; Nagao K; Kinoshita M; Watanabe S; Kuwabara Y; Nakashima Y; Takanabe-Mori R; Nishi E; Hasegawa K; Kita T; Kimura T
    Cardiovasc Res; 2010 Sep; 87(4):656-64. PubMed ID: 20495188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity profile of trastuzumab.
    Ewer SM; Ewer MS
    Drug Saf; 2008; 31(6):459-67. PubMed ID: 18484781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab--mechanism of action and use in clinical practice.
    Hudis CA
    N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
    [No Abstract]   [Full Text] [Related]  

  • 20. PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
    Xu Z; Gao Z; Fu H; Zeng Y; Jin Y; Xu B; Zhang Y; Pan Z; Chen X; Zhang X; Wang X; Yan H; Yang X; Yang B; He Q; Luo P
    Cardiovasc Res; 2023 May; 119(5):1250-1264. PubMed ID: 36651911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.